- Lexaria’s
DehydraTECH(TM) drug delivery platform a feasible and healthier
alternative to other delivery methods
- The
fast-acting, high absorption technology improves dipping experience and
consumer satisfaction
- Company
expects to more than double its 2019 revenue this year, will pursue a new
capital markets strategy to qualify for listing on a nationally recognized
U.S. exchange
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global
innovator in drug-delivery platforms and one of the few companies active in the
field of cannabis to have developed formal relationships with Fortune 500
industry leaders, is experiencing strong demand from many companies requesting
pre-processed DehydraTECH(TM)-enhanced bulk powders.
The company’s revolutionary drug delivery platform
DehydraTECH(TM) accelerates human intestinal cell absorption of bioactive
substances administered without the need for inhalational dosing,
co-administration with sugars or sweeteners, and other unhealthy practices. It
is applicable to a wide variety of bioactive substances, including cannabis and
nicotine. Utilization of the DehydraTECH(TM) drug delivery platform increases
the absorption levels of CBD in human intestinal cells by 499%. As much as
1,937% more CBD is delivered into animal brain tissue after 8 hours using the enhanced
technology in comparison with generic industry MCT coconut-oil formulations,
according to recent studies.
Vaping and smoking have been shown to be dangerous methods
of delivering drugs. Lexaria developed its technology as a safe and fast
delivery method of bioactive substances via oral ingestion by bypassing
potentially unhealthy practices such as inhalation. Proven to deliver up to 10
times more active ingredients in comparison to traditional edible,
DehydraTECH(TM) is the first platform of its kind that allows users to access
the primary benefits of inhalation – speed and efficiency – while circumventing
the risks of inhalation.
The company currently has 16 patents granted and more than
60 patent applications worldwide. It is the only company to hold a patent for
improved delivery of nicotine and all non-psychoactive and psychoactive
cannabinoids, including tetrahydrocannabinol. The platform reduces the time of
onset of THC by four times on average (http://ibn.fm/AvVxl).
Lexaria also obtained two patents for treating certain
conditions including, but not limited to heart disease, neurological diseases
such as Alzheimer’s, Parkinson’s, schizophrenia, and others. The platform has
potential applications to assist treatment of the common form of dementia as
well as other nervous system diseases.
In 2019, the company finalized a new contractual
relationship with a GMP-certified, FDA registered production company to get
enhanced DehydraTECH(TM) powders to market in the U.S. with current capacity of
roughly 200,000 servings per day (http://ibn.fm/T0TMV).
The versatility and multiple potential applications of the
DehydraTECH(TM) drug delivery platform, paired with the proven benefits it
offers over other delivery methods, are some of the key factors driving demand
and revenue growth for Lexaria Bioscience in 2020. The company expects to more
than double its 2019 revenue this year from both existing clients and by
leveraging a rich pipeline of prospective additional clients.
The company has already taken steps to increase the reach of
its technology via a recent agreement with Cannadips Cannabis (http://ibn.fm/OUJa6). Under
the definite agreement, Cannadips will use Lexaria’s technology to enhance its
products available in California and nationwide. More specifically,
DehydraTECH(TM) will be able to reduce throat irritation normally associated
with some terpenes, which are part of the base ingredients of Cannadips THC.
The 10-year licensing agreement is expected to considerably improve dipping
experience and consumer satisfaction.
The expected revenue increase will support Lexaria’s future
growth plans and its new capital markets strategy to qualify for listing on a
nationally recognized U.S. exchange. This move is anticipated to significantly
increase the company’s market visibility and expand its customer base.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
